Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
Early results appear promising for frontline asciminib in patients with chronic phase chronic myeloid leukemia, according to researchers.
Researchers sought to determine if discontinuation of TKI therapy was safe for pediatric patients with CML.
Illegitimate online pharmacies are selling imatinib without a prescription, making false claims about being registered with regulatory bodies, and failing to provide patients with drug-related warnings.
The patients were randomly assigned 2:1 to asciminib 40 mg twice daily or bosutinib 500 mg once daily.
The investigators performed univariate and multivariate analyses to identify factors associated with the loss of MMR.
From 2017 to 2019, the number of beneficiaries prescribed at least 1 oral TKI increased from 154 beneficiaries to 212 beneficiaries.
Investigators reported findings from the ongoing SARS2 SeroPrevalence And Respiratory Tract Assessment (SPARTA) study.
In CML, second malignancies are rare and trends remain poorly understood.
“Excellent” overall survival is achievable with currently available drugs, according to researchers.